A Food-Derived Dietary Supplement Containing a Low Dose of Iron Improved Markers of Iron Status Among Nonanemic Iron-Deficient Women.

What Was Tested

The paper reports a study of Copper (Supplement), published as a clinical trial.

Iron deficiency is the most common nutrient deficiency in the world.

While deficiency can often be resolved through dietary supplementation with iron, adverse events are common and frequently preclude compliance.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

A pilot clinical trial (NCT02683369) was conducted among premenopausal women with nonanemic iron deficiency that was verified by blood screening.

How the Study Was Run

In design terms this was a pilot study.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

Primary outcomes were markers of iron status (serum ferritin, hemoglobin, soluble transferrin receptor, total body iron stores) and secondary outcomes were self-reported fatigue and energy.

All outcomes were assessed at baseline and 8 weeks.

Dependent samples t test and Wilcoxon signed-rank test were used to analyze outcomes.

What Was Measured

Topics PubMed links to this paper include Deficiency Diseases, Dietary Supplements, Iron, Iron Deficiencies, Nutritional Status and Pilot Projects.

The authors tagged it with the keywords ferritin, folate, hemoglobin, nonanemic iron deficiency, soluble transferrin receptor and total body iron stores.

What This Means in Plain Language

The paper is a pilot study of Copper (Supplement).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Journal of the American College of Nutrition), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.